7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Insulin Resistance D007333 99 associated lipids
Weight Gain D015430 101 associated lipids
Glioma D005910 112 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Nielsen KL et al. Biglycan deficiency interferes with ovariectomy-induced bone loss. 2003 J. Bone Miner. Res. pmid:14672350
Amizuka N et al. Defective bone remodelling in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756238
Kawana F and Sasaki T Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756239
Okuma K et al. Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. 2003 J. Virol. pmid:12857926
Cheng X et al. The TNF receptor superfamily: role in immune inflammation and bone formation. 2003 Immunol. Res. pmid:12857975
Shin MM et al. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. 2003 Exp. Mol. Med. pmid:12858015
Gehrke T et al. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. 2003 Scand. J. Rheumatol. pmid:14690142
Glossop JR et al. No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. 2003 J. Rheumatol. pmid:12858434
Hampson G et al. Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. 2003 Osteoporos Int pmid:12904840
Stolina M et al. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. 2003 Clin. Immunol. pmid:14697750
Misra M et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. 2003 J. Clin. Endocrinol. Metab. pmid:12915674
Lonergan M et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. 2003 J. Clin. Endocrinol. Metab. pmid:12915677
Kapczuk K et al. [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. 2003 Ginekol. Pol. pmid:12916277
Liu JZ et al. [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. 2003 Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi pmid:12916296
Bendre MS et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. 2003 Bone pmid:12919697
Tabb MM et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. 2003 J. Biol. Chem. pmid:12920130
Park HR et al. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. 2003 J. Korean Med. Sci. pmid:12923331
Naylor KE et al. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. 2003 J. Clin. Endocrinol. Metab. pmid:14602774
Paloneva J et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. 2003 J. Exp. Med. pmid:12925681
Fukushima H et al. Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. 2003 Eur. J. Oral Sci. pmid:12887401
Ito R et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. 2003 Virchows Arch. pmid:12838418
Hayashi S et al. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. 2003 J. Immunol. pmid:14607912
Terpos E et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. 2003 Int. J. Cancer pmid:12845688
Schett G et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. 2003 Arthritis Rheum. pmid:12847699
Gruber HE and Rude RK Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. 2003 Biotech Histochem pmid:14989640
Wagner TU et al. The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo. 2003 Adv Space Res pmid:15000082
Nakamura M et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. 2003 Endocrinology pmid:14500574
Zhang Z et al. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. 2003 J. Immunol. pmid:14500659
Ueno Y et al. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. 2003 J. Cell. Biochem. pmid:14505343
Kaneyama K et al. Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. 2003 Int J Oral Maxillofac Surg pmid:14505625
Miyahira Y et al. Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. 2003 J. Immunol. pmid:14662831
Seidlova-Wuttke D et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. 2003 Eur. J. Endocrinol. pmid:14514351
Hortobagyi GN Novel approaches to the management of bone metastases. 2003 Semin. Oncol. pmid:14613037
Voskaridou E et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. 2003 Br. J. Haematol. pmid:14616979
Uemura H et al. Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. 2003 Bone pmid:14623063
Novack DV TSH, the bone suppressing hormone. 2003 Cell pmid:14567908
Abe E et al. TSH is a negative regulator of skeletal remodeling. 2003 Cell pmid:14567913
Zhao ZM et al. [The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. 2003 Zhonghua Xue Ye Xue Za Zhi pmid:14575594
Boyan BD et al. Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. 2003 Eur Cell Mater pmid:14577052
Zhang J et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. 2003 Cancer Res. pmid:14633717
Grigorie D et al. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. 2003 Rom J Intern Med pmid:15526523
Kanatani M et al. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. 2003 J. Cell. Physiol. pmid:12767054
Nagata N et al. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. 2003 Bone pmid:14555278
Grimaud E et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. 2003 Am. J. Pathol. pmid:14578201
Bord S et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. 2003 Bone pmid:12633785
Coen G et al. Serum leptin in dialysis renal osteodystrophy. 2003 Am. J. Kidney Dis. pmid:14582047
Garber K Why it hurts: researchers seek mechanisms of cancer pain. 2003 J. Natl. Cancer Inst. pmid:12783923
Chagraoui H et al. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. 2003 Exp. Hematol. pmid:14585373
Liu B et al. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. 2003 J. Oral Pathol. Med. pmid:12787044
Eaton CL and Coleman RE Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. 2003 Cancer Treat. Rev. pmid:12787713
Fahrleitner-Pammer A et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. 2003 Wien. Klin. Wochenschr. pmid:12793029
Dovio A et al. Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. 2003 Clin. Cancer Res. pmid:12796409
Flick LM et al. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. 2003 J. Orthop. Res. pmid:12798068
Khapli SM et al. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. 2003 J. Immunol. pmid:12816992
Kawase Y et al. Bone malformations in interleukin-18 transgenic mice. 2003 J. Bone Miner. Res. pmid:12817749
Kikuchi T et al. Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. 2003 J. Dent. Res. pmid:12821717
D'Elia HF et al. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. 2003 Arthritis Res. Ther. pmid:12823855
Knudsen ST et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. 2003 Eur. J. Endocrinol. pmid:12824864
Fox SW et al. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. 2003 J. Immunol. pmid:12646633
Varsani H et al. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). 2003 Rheumatology (Oxford) pmid:12649407
Wise GE et al. Regulation of osteoprotegerin gene expression in dental follicle cells. 2003 J. Dent. Res. pmid:12651935
Schoppet M et al. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. 2003 Circulation pmid:12654623
Nimmanapalli R and Bhalla K Targets in apoptosis signaling: promise of selective anticancer therapy. 2003 Methods Mol. Biol. pmid:12777745
Zheng B et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. 2003 Blood pmid:12689928
Moreno JL et al. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. 2003 Blood pmid:12689929
Dovio A et al. Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. 2003 J. Endocrinol. pmid:12697042
Nakano M et al. Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. 2003 Oral Dis pmid:12657033
Ra JS et al. Osteoprotegerin inhibits proliferation of myeloid progenitor cells. 2003 J. Hematother. Stem Cell Res. pmid:12662434
Szalay F et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. 2003 J. Hepatol. pmid:12663228
Okada Y et al. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. 2003 J. Biol. Chem. pmid:12665515
Bell NH RANK ligand and the regulation of skeletal remodeling. 2003 J. Clin. Invest. pmid:12697730
Eghbali-Fatourechi G et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. 2003 J. Clin. Invest. pmid:12697741
Enomoto H et al. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. 2003 J. Biol. Chem. pmid:12697767
Nakashima T et al. RANKL and RANK as novel therapeutic targets for arthritis. 2003 Curr Opin Rheumatol pmid:12707582
Johnson-Pais TL et al. Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. 2003 Int. J. Cancer pmid:12673693
Zaidi M et al. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. 2003 J. Bone Miner. Res. pmid:12674320
Tanaka S et al. Signal transduction pathways regulating osteoclast differentiation and function. 2003 J. Bone Miner. Metab. pmid:12720046
Valleala H et al. Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. 2003 Eur. J. Endocrinol. pmid:12720535
Yonou H et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. 2003 Cancer Res. pmid:12727825
Capparelli C et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. 2003 J. Bone Miner. Res. pmid:12733724
Wong T et al. Therapeutic implications for interferon-alpha in arthritis: a pilot study. 2003 J. Rheumatol. pmid:12734885
Lipton A Bisphosphonates and metastatic breast carcinoma. 2003 Cancer pmid:12548585
Demers LM Bone markers in the management of patients with skeletal metastases. 2003 Cancer pmid:12548589
Body JJ et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. 2003 Cancer pmid:12548591
Xing L et al. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. 2003 J. Bone Miner. Res. pmid:12568403
Cao J et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. 2003 J. Bone Miner. Res. pmid:12568404
Johnson-Pais TL et al. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. 2003 J. Bone Miner. Res. pmid:12568416
Clohisy JC et al. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. 2003 J. Orthop. Res. pmid:12568950
Fahrleitner A et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. 2003 Bone pmid:12584041
Lanzi R et al. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. 2003 Eur. J. Endocrinol. pmid:12590637
Shipman CM and Croucher PI Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. 2003 Cancer Res. pmid:12615702
Hamzei M et al. Osteoclast stimulating and differentiating factors in human cholesteatoma. 2003 Laryngoscope pmid:12616193
Siggelkow H et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. 2003 J. Bone Miner. Res. pmid:12619938
Toraldo G et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. 2003 Proc. Natl. Acad. Sci. U.S.A. pmid:12490655
Rude RK et al. Magnesium deficiency: effect on bone and mineral metabolism in the mouse. 2003 Calcif. Tissue Int. pmid:12370796
Takayanagi H [Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. 2003 Seikagaku pmid:14748148
Chen X et al. Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. 2003 J. Nutr. Biochem. pmid:12873716
Bridgham JT and Johnson AL Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. 2003 Biochem. Biophys. Res. Commun. pmid:12878204
Riggs BL et al. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. 2003 Osteoporos Int pmid:12879223
Sasaki T Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. 2003 Microsc. Res. Tech. pmid:12879416

Table of Content